HDM2 protein overexpression and prognosis in primary malignant melanoma

D. Polsky, K. Melzer, C. Hazen, H. Kamino, J. G. Spira, A. W. Kopf, Ronald O. Perelman, Iman Osman, K. S. Panageas, K. Busan, M. Drobnjak, C. Cordon-Cardo, A. Houghton

Research output: Contribution to journalArticlepeer-review

70 Scopus citations


Overexpression of the oncogene HDM2 is observed in a substantial proportion of melanomas, including noninvasive and thin lesions, suggesting that HDM2 overexpression may be an early event in melanocyte transformation. To determine the role of HDM2 in the clinical progression of melanoma, we examined whether its expression was associated with patient survival. From November 1972 through November 1982, 134 patients with melanoma who participated in the New York University Melanoma Cooperative Group were studied, if representative tissues and follow-up were available. HDM2 protein expression was assessed immunohistochemically. Unexpectedly, we observed that HDM2 overexpression was statistically significantly associated with improved disease-free survival (relative risk [RR] = 0.47, 95% confidence interval [CI] = 0.24 to 0.89; two-sided X2 p =.021) and overall survival (RR = 0.55, 95% CI = 0.33 to 0.94; two-sided X2 P =.027) in multivariable analysis. HDM2 overexpression appears to be an independent predictor of survival for patients with primary melanoma; however, larger prospect' studies are required for validation.

Original languageEnglish
Pages (from-to)1803-1806
Number of pages4
JournalJournal of the National Cancer Institute
Issue number23
StatePublished - 4 Dec 2002
Externally publishedYes


Dive into the research topics of 'HDM2 protein overexpression and prognosis in primary malignant melanoma'. Together they form a unique fingerprint.

Cite this